PPARδ agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-21 and is reviewed periodically as new material appears.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Irregular periods: periods may stop completely or may be less frequent. When they do happen, periods can be very heavy. There may be menstrual bleeding without ovulation, too; around 40% of women with PMOS who have a regular cycle have periods without ovulation. Infertility: PMOS is one of the leading causes of infertility in women. A "male" pattern of hair growth, including hair on the chin, upper lip, chest, upper thighs, and on the belly. This growth pattern, called hirsutism, is present in about 60% of women with PMOS. Acne: Acne is typically severe, persists beyond adolescence, or continues despite standard treatment. Pattern hair loss (androgenic alopecia), at the top of the scalp Skin issues, such as oily skin or a condition where dark, thick, and "velvety" patches can form (acanthosis nigricans) The ovaries might be larger than normal, with many small fluid-filled sacs that surround eggs ("follicles"). Testosterone levels are usually elevated: one meta-analysis showed testosterone levels to be 1.5 times higher in women with PMOS compared to women without PMOS.
==== Immunomodulators ==== Baricitinib (Olumiant) – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 2 inhibitors, TYK2 kinase inhibitor Deuruxolitinib (Leqselvi) – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 2 inhibitor Ritlecitinib (Litfulo) – oral – alopecia areata – Emt protein-tyrosine kinase inhibitor, Janus kinase 3 inhibitor
== Structure == AgRP is a paracrine signaling molecule made of 112 amino acids (the gene product of 132 amino acids is processed by removal of the N-terminal 20-residue signal peptide domain). It was independently identified by two teams in 1997 based on its sequence similarity with agouti signalling peptide (ASIP), a protein synthesized in the skin controlling coat colour. AgRP is approximately 25% identical to ASIP. The murine homologue of AgRP consists of 111 amino acids (precursor is 131 amino acids) and shares 81% amino acid identity with the human protein. Biochemical studies indicate AgRP to be very stable to thermal denaturation and acid degradation. Its secondary structure consists mainly of random coils and β-sheets that fold into an inhibitor cystine knot motif. AGRP maps to human chromosome 16q22 and Agrp to mouse chromosome 8D1-D2.
Sources: en.wikipedia.org
Despite these promising findings, translation into clinical applications in humans remains limited, and further research is required to evaluate the safety, efficacy, and feasibility of therapeutic strategies inspired by this model.
Natural fermentation predates human history. Since ancient times humans have exploited fermentation, most likely having unintentionally discovered the process. To store excess foods, humans placed the items in a container which were probably later forgotten, and over time yeast and bacteria started to grow. The earliest archaeological evidence of fermentation is the 13,000-year-old residue of beer, with the consistency of gruel, found in a cave near Haifa, Israel. Another early alcoholic drink, made from fruit, rice, and honey, dates from 7000 to 6600 BC in the Neolithic Chinese village of Jiahu. Winemaking dates from circa 6000 BC in Georgia in the Caucasus area. Seven-thousand-year-old jars containing the remains of wine, now on display at the University of Pennsylvania, were excavated in the Zagros Mountains in Iran. There is strong evidence that people were fermenting alcoholic drinks in Babylon (ca. 3000 BC), ancient Egypt (ca. 3150 BC), pre-Hispanic Mexico (ca. 2000 BC), and Sudan (ca. 1500 BC).
Cross-flow membrane filtration technology has been used widely in industry around the globe. Filtration membranes can be polymeric or ceramic, depending upon the application. The principles of cross-flow filtration are used in reverse osmosis, nanofiltration, ultrafiltration and microfiltration. When purifying water, it can be very cost-effective in comparison to the traditional evaporation methods. In protein purification, the term tangential flow filtration (TFF) is used to describe cross-flow filtration with membranes. The process can be used at different stages during purification, depending on the type of membrane selected. In the photograph of an industrial filtration unit (right), it is possible to see that the recycle pipework is considerably larger than either the feed pipework (vertical pipe on the right hand side) or the permeate pipework (small manifolds near to the rows of white clamps). These pipe sizes are directly related to the proportion of liquid that flows through the unit. A dedicated pump is used to recycle the feed several times around the unit before the solids-rich retentate is transferred to the next part of the process.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.